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Abstract 
The development of big data research methods and the information asymmetry problems in the financial market lead to 
the new issue of homo sociologicus, which has become a new way of thinking and has hoped to find the cause of asset 
pricing problem in the market. Crony capitalism is prevalent in the emerging and developing countries. It leads to 
wealth inequalities. Therefore, behavioral finance theory can help individual investors make investment decisions and 
help stock prices to reflect their true values. This study finds that the biotechnology industry does not exist an efficient 
market based on two OTC biotech companies, OBI Pharma and TaiMed Biologics, for the period 2015.11.23~2016.6.7. 
The results show that the technical analysis tested in this study can lead to trading profits and investors can increase 
their trading profits based on the mean reversion characteristic of company price differences. 
Keywords: mean reversion, program trading, Granger causality test, crony capitalism, biotech industry, efficient market 
1. Introduction 
On 7 May 2016, the Economist published the crony capitalism index which measured the easiness that people can make 
money based on relations. Taiwan which had billionaire wealth representing 3.2% of GDP was ranked number 10 
around the world. Crony capitalism is referred to the close political connection between business people and the 
government. Under crony capitalism, the success to fortune depends on “who” the businesses have close relations to 
rather than business skills. The crony capitalism index also showed that Taiwan had more serious collusion problem 
than China and United states, which was ranked number 11 and 16, respectively, in 2016. 
OBI Pharma Inc. was established in 2002 and was a 100% re-investment by Optimer Phamaceuticals (short for, OPTR) 
founded in 1998 by the former chair of Academia Sinica, Chi-Huey Wong
1
, who was an authority on carbohydrates 
field, and by the current board of director, Michael Chang. In September 2012, Samuel Yin, the chairman of Ruentex 
Financial Group bought the shares of OBI Pharma held by OPTR at $31 for a total of US$ 60 million. In December, 
OBI Pharma was listed in the emerging stock market at $90 which was the triple of the original cost. In March 2015, 
OBI Pharma was traded at the OTC market at $310
2
, which was ten times higher than the original cost. In 2006, 
Chi-Huey Wong was the first person with dual nationality to serve as the chair of Academia Sinica. In June 2007, 
Ing-Wen Tsai
3
 who was the Vice Premier of Executive Yuan, and Jin-Pyng Wang, who was the President of Legislative 
Yuan, successfully pushed the “Biotech and New Pharmaceutical Development Act” to be passed. The Act4 allowed 
governmental researchers to participate in new pharmaceutical development and be distributed a maximum of 40% 
technology stocks. With funding from the government, the biotechnology and new pharmaceutical were hoped to 
become a cash cow industry. However, as many new drugs are under development, there was a large difference between 
the production value and market value. There was no operating income or P/E ratio for evaluating the company. All 
companies relied on the “dream ratio”. According to the Q4 financial report of OBI Pharma, the company’s capital was 
approximately 1.5 billion while the market value was as high as 112 billion. The operating income was -1,063 million, 
and non-operating income was only 123 million. As a result, when the blind experiment of a breast cancer drug 
(OBI-822) failed on 19 February 2016, the stock price dropped sharply from $718 to $321 on 25 April 2016; that is, a 
drop of 55.2%. At the same time period, the Taiwan stock market increased by 3.6%. As the biotech and new 
pharmaceutical industry was highly technology intensive, this caused company information asymmetry problem and 
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allowed for speculation by government officers and businesses. (Please refer to the Appendix for the political ties of 
OBI Pharma and TaiMed Biologics.) The top management of OBI Pharma even intensively sold their holdings in the 
fourth quarter of 2015 before the results of blind experiment. The security lending also rocketed to 7,219,000 shares, 
and amounted to $40 billion. In contrast, the investors lost their savings. 
According to the reports by FSC, by the end of May 2016, the individual traders in the market had dropped to 47%, 
compared to a high of 70% in the past. The financed trading volume also reduced from 207.3 billion to 135.2 billion 
(-34.8%). The Taiwan stock market showed an escaping sign by individual investors. Due to the lack of information, 
individual investors often engaged in short-term trading, tracing highs and selling at lows. Therefore, this study aims to 
use behavioral finance theory to help individual investors develop appropriate investment strategies. At the same time, 
the stock market can reflect its real value. The Taiwan stock market can change from a highly turnover market and 
become a mature stable market.  
This study aims to propose investment strategies for investors based on the case study of a failed blind experiment of 
OBI Pharma. The organization of this paper is as follows. Section 2 provides the literature review. Section 3 discusses 
the event study method, Granger causality model and program trading. Section 4 provides the data source. Section 5 
provides the empirical results and analysis. Lastly, a conclusion is provided in Section 6. 
2. Literature Review 
Fama (1970) proposes the efficient market hypothesis and suggests that all investors in the market are “rational”. 
However, since1980, more and more evidence points to anomalies in the market due to investors’ perception bias. 
Therefore, there occurs some typical investment behavior. For example, Tversky and Kahneman (1973) propose the 
“availability heuristics” and suggest that people are not able to extract all related information from past memory. People 
tend to believe in events that they can easily think of or remember as events that happen often. Tversky and Kahneman 
(1982) suggest the “representativeness heuristics” and argue that when people evaluate the possibility of an event, they 
often over rely on past experience of a similar event. In addition, Shefrin and Statman (1994) suggest that people are 
often overconfident and believe that their judgements are correct. Tversky and Shafir (1992) suggest that people have 
“qusi-magical thinking” and believe that they can change something that is already a fact. People also dislike losses and 
regrets, and have disposition effect. As a result, the behavioral finance argues that investors are “bounded rational”. 
Cohen, Frazzini and Malloy (2008) use social connection (also referred to as social networks or social ties) to test the 
information flow in the securities market. Their results show that investment performance of asset management that has 
social networks is significantly higher than that does not have social networks. The difference in yearly return between 
the two is 7.8%. Private information can pass between fund managers, CEO and financial analysts through alumni 
relations. This affects the asset pricing, asset allocation and investment returns. Therefore, they are referred to as “homo 
sociologicus”. 
Examples of social relations include alumni relations, colleague relations, peer relations, business relations, geographic 
position relations and military colleagues. Hong et al. (2005) find that the American people’s participation in the market 
is affected by social interactions. The more people interact with their neighbors, the higher the degree of socialization, 
and therefore, the more participation in the stock markets. Kuhnen (2009) examines the open fund managers (or 
directors) and consulting firms between 1993 and 2002 and finds that the employment relationship between the two is 
based on past interaction experience. Their business relations can help improve information efficiency. However, due to 
the inefficient favoritism restriction in corporate governance, investors do not benefit from such social ties. Hwang et al. 
(2009) follow Fortune 100 companies between 1996 and 2005 and find that among the 87% of traditional independent 
directors, only 62% are real independent directors and the average annual remuneration dropped by US$1.2 million 
after considering social relation networks. Fracassi et al. (2012) use S&P 1500 panel company data to examine the 
external social relations of directors and CEO. Their results show that dominant CEOs will appoint directors whom they 
have strong social ties. When the corporate governance mechanisms are absent, external social ties of CEO and 
directors will reduce company value. In particular, when the ties are strong, they are likely to engage in 
value-decreasing acquisitions. In other words, social networks will weaken the monitoring function of directors. In 
addition, Fracassi (2014) finds that when making company decisions, CEOs are likely to be affected by their peer CEOs. 
That is, the more strong the ties between companies, the more alike the capital investment. Therefore, in this study, we 
adopt two brother companies, OBI Pharma and TaiMed Biologics, as the case study to examine the appropriate 
investment strategies when investors are facing with crony capitalism. The chairman of OBI Pharma and the chair of 
Academia Sinica have alumni relations at MIT. Engelberg (2013) uses the US data between 2000 and 2007 and finds 
that when the CEO of listed companies have alumni relations with other CEOs, their compensations are positively 
related; adding one alumni relation will increase compensation by US$ 17,000. Early studies, including Shiller (1979) 
and LeRoy and Porter (1981), have found overreactions in speculative asset pricing. This phenomenon is inconsistent 
with the efficient market hypothesis. Investors often make investment strategies based on noise trading and positive 
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feedback trading. DeBondt and Thaler (1985, 1987) use NYSE listed company data from 1926 and 1982 and find that 
overreactions exist in the market. The return of “losing group” (which consists of 35 worst performing stocks in past 
three years) is 8%  higher in yearly average than that of “winning group” (which consists of 35 best performing stocks 
in the past three years) and is 25% higher in three-year returns. Fama and French (1988) also find that three to five year 
stock market returns are negatively autocorrelated. The result suggests that price overreaction will recover in the 
long-run. Poterba and Summers (1988) also use variance ratio test to examine the US market between 1871 and 1986 
and 17 other countries between 1957 and 1985. The evidence also shows that stock market returns are positive 
correlated in the short term and negative autocorrelated in the long term. 
Moreover, De Long et al. (1990) argue that noise trading will cause overreactions. When the asset price is too high or 
too low, an inverse correction is likely. Therefore, autocorrelation is observed in the long-run returns. Cutler, Poterba 
and Summers (1991) find that negative autocorrelations exist in three to five year stock market returns. The evidence 
suggests that price under-reacts initially and corrects gradually. Daniel, Hirsheifer and Subrahmanyam (1998) develop a 
model for describing investor behavior (referred to as DHS model). The DHS model divides investors into two groups, 
informed and uninformed investors. Uninformed investors disobey judgment bias. The stock prices are set by informed 
investors who suffer from over-confidence and over self-preference. Due to over-confidence, investors exaggerate the 
precision of price related private information. On the other hand, over self-preference causes continuous short-term and 
long-term conversions in stock returns. Barberis, Shleifer and Vishney (1998) argue that as investors do not realize that 
the real returns of risky assets follow random walk, they may overreact or under-react. 
Thaler (1992) develops a method for measuring short-term price reversion of losers and risk volatility. If the stock price 
rises or falls by 10%, the objective risk is unlikely to have such a large volatility. Thus, in a very short period of time, 
we can observe the phenomenon of mean reversion. The phenomenon is likely to be caused by reasons other than size 
or objective risk. In addition, Bremer and Sweeney (1988) test the short-term price changes of Fortune 500 companies 
between July 1962 and December 1986 and find similar daily return patterns reported by Brown and Van Harlow (1988) 
on long-term winners and losers. 
Event studies can be used to test how corporate environmental changes affect finance and examine the changes in stock 
prices before and after the event. Daily and Johnson (1997) use LISREL analysis and find out the authority of CEOs is 
related to corporate performance. Mazur (1999) adopts 2500 survey data of Burson-Marsteller and finds that the image 
of CEOs will affect the evaluation of stock analysts on companies. This will then affect investors’ viewpoint on 
companies. During the 1997 stock market depression, stock prices of companies with top 10 best image CEOs recover 
four times faster than other companies. 77% of respondents are willing to invest in companies with better CEO images. 
Rozeff and Zaman (1998) also find that the trading behavior of corporate insiders is not random. When the stock returns 
are low, insiders purchase more stocks and vice versa. Bergman and Roychowhury (2008) find that managers will 
strategically adjust earnings disclosure policy based on investors’ sentiment. When investors’ sentiment is low, they will 
increase the prediction for future earnings growth. In addition, Shleifer (1986) finds that since September 1976, while 
the basic values of newly added S&P 500 composite companies do not vary, their stock prices increase by about 3% 
when they are added to the index. The abnormal returns usually last for at least one month. In this study, the OBI 
Pharma initially (2015.8.31) planned to reveal the results of blind experiment on March 2016. On 12 November 2015, 
the company announced to forward the date to February 2016; on that day, the stock price was $439.5. On the next day 
(13 November 2015), the company was included in the MSCI index. One month later (18 December 2015), the stock 
price of OBI Pharma reached its highest of $755 (i.e., an increase of 72%). 
Thaler (1992) argues that fundamental changes will cause changes in market value. For instance, when company X 
acquires company Y, the market increases by 10%. To test if this is an unbiased estimate, we can examine the price five 
years later. However, prices often have large variations, and there is no one correct method for testing this hypothesis. 
The relations in this study are even more complex
5
, including teacher-student relations (i.e., Samuel Yin was the student 
of Jin-Pyng Wang at a naughty students training class at junior high school), alumni relations (i.e., Chi-Huey Wong and 
Michael Chang both studied at MIT), political relations (i.e., Jin-Pyng Wang and Ing-Wen Tsai served different political 
parties but they both supported the enactment of the new biotech Act), business relations (i.e., Ing-Wen Tsai, the 
chairman of Yu Chang Biotech, transferred her shares to Samuel Yin), father-daughter relations (i.e., Chi-Huey Wong 
and Yu-Siou Wong), public servant relations (i.e., Shih-Jen Li and Chi-Huey Wong had monitoring relations), tax 
matters (i.e., Chi-Huey Wong’s gift tax), stockholding matters (i.e., Chi-Huey Wong did not declare changes in 
stockholdings). In short, the case company in this study has the following issues: conflict of interest avoidance issue, tax 
matters, omission of disclosing stockholdings, and prior short-selling.These relations cannot be modeled using 
economic or financial models. Therefore, this study develops a new testing method by using a quantitative model and 
optimized program trading. Specifically, the event study method and a two-stage test are adopted to seek for a stable 
investment strategy. This study aims to find an investment strategy that improves investors’ investment efficiency using 
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the mean reversion feature in stock prices. That is, if the diversion in stock price and index exists as shown by technical 
analyses and investors are able to improve their trading profits based on positive feedback trading model, then there is 
evidence that stock prices are featured by mean reversion. 
3. Methods 
3.1 Event Study Model and Estimation Methods 
Based on Fama, Fisher, Jensen and Roll (1969), this study adopts the event study method to test the effect on stock 
prices when OBI Pharma announced a failure in blind experiment. Using the data obtained from Taiwan Economic 
Journal (TEJ), GARCH model is applied to test abnormal returns. The event study model is defined below: 
 
 
 
 
 
 
 
 
 
t：time      T：Estimation period     W：Event period 
Estimated return based on the market model is as follows: 
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Due to the trading restriction after the announcement, the event period is 30 days, including 15 days before the 
announcement of blind experiment failure on 21 February 2016, which is the event date, (i.e., the estimation window) 
and 15 days after the event date (i.e., the event window). That is, a total of 61 days for testing if AR and CAR are 
significantly different from zero. Also, TAIEX is used as the benchmark for the 200-day estimation period. 
3.2 Vector Autoregression (VAR) and Granger Causality Model and Estimation Methods 
The theoretical models and estimation methods in this study follows Lan et al.’s (2014) method and uses vector 
autoregression model as proposed by Sims (1980). By including lagged estimates of the variables in the model, we are 
able to predict a relevant time series system and the dynamic impact of random noises on this system. This study uses 
OBI Pharma (stock ID 4174) as the base variable and TaiMed Biologics (stock ID 4147) as its brother company. There 
exists a causal relationship within variables. Hence, in the following sections, OBI Pharma is the base variable. The two 
variables in the model are A4174 (OBI Pharma) and A7447 (price difference between OBI Pharma and TaiMed 
Biologics). The variables
2t1t
y,y  at time t are composed of variables in the prior time k and error term. Taking VAR(1) 
(i.e., k = 1) as an example:  
t1 t2 
t3 t4 
T 
Estimation period 
200 days 
W 
Event period 
Event day 
15 days 15 days 
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 the error term t is white noise;  is the constant, a is the coefficient 
and Ω is the positive definite variable and covariance matrix.  
The error term t can be same period correlated but cannot be correlated with its lagged estimates or variables on the 
right-hand side of the function. From here, we can test the causality relationship. Moreover, as the economic theory has 
no definite conclusion on the relationship between stock price and price difference, the causality analysis developed by 
Granger (1969, 1988) can used to examine the relation between two. That is, by examining whether a causal 
relationship exists between current period price differences (A7447) and A4174 (past stock price of OBI Pharma), we 
can determine the degree to which the past value of A4174 can be used to predict the value of A7447. If adding the 
lagged value of A4174 can increase the explainability or the correlation coefficient of A4174 and A7447 is statistically 
significant, the result suggests that A7447 is the Granger cause of A4174.  
3.3 Experimental Design and Estimation Methods 
The experiment used in this study includes two models. Model 1 includes only one set of data (data1). Model 2 is based 
on program trading design concept of Williams (1999). In order to enhance the trading performance, one more set of 
data (apart from data1) is included in the model. We use the price difference of corresponding company as the filter. 
Therefore, the following trading strategies are adopted. We use the base company (data1, OBI Pharma) and the price 
difference of data2 (OBI Pharma) and data3 (TaiMed Biologics) as the benchmark. The diversion trading
6
 based on 
technical analysis in program trading is designed as follows:  
1. The benchmark uses RSI as oscillators. Data1 is the stock price of the base company, OBI Pharma. 
2. The price difference of two companies is calculated and used as the benchmark. Specifically, the stock price of 
data2 (OBI Pharma) is deducted from the stock price of data3 (TaiMed Biologics) and times 100. 
3. If within nine K bars, the RSI is above 70 (or below 30) for at least twice, this can be included. In addition, if the 
closing price is at its new high (or low) within nine K bars while RSI does not reach its new high (or low) at the 
same time, we note down the value of K bar at that point. In the future, if the stock price touches this low (or high) 
point of the K bar, the strategy is to sell (or buy). 
Moreover, in this study MultiCharts program trading is used to do back-testing of the first stage 
(2015.11.23~2016.02.21) and to compare the trading performance at optimal conditions. The optimal coefficient is 
obtained when we have up to nine K bars and RSI that is above 70 (or below 30). It is then used in the second stage 
(2015.11.23~2016.06.07) to estimate the Taiwan stock market. By doing so, we can determine if trading performance 
can be enhanced by using the price difference between two companies.  
4. Data 
This study examines whether including the price difference of OBI Pharma and TaiMed Biologics can improve the 
stock market trading performance. The daily price data used in this study includes the stock price (30m) of OBI Pharma 
and TaiMed Biologics obtained from XQ database. To ensure the benchmarks are comparable, the stock prices of 
TaiMed Biologics are obtained from the time it listed on the OTC market. For the experimental design, the data period 
for the first stage covers from 2015.11.23 to 2016.02.21 (i.e., 522 sample points) and the second stage covers from 
2015.11.23 to 2016.06.07 (i.e., 1197 sample points). The experimental method is to use the optimized simulated 
parameters obtained from the first stage in the second stage. All data mentioned above are calculated at level except for 
those original data that is I(1). These need to be differentiated and symbolized by D. Also, a transaction cost of 1% of 
the price of OBI Pharma (i.e., $5) is assumed for all models. 
5. Results  
5.1 Abnormal Returns around the Announcement of Blind Experiment Failure 
5.1.1 OBI Pharma’s Abnormal Returns 
Figure 1 shows the AR/CAR line chart of GARCH model. Twenty days before the announcement of blind experiment 
failure by OBI Pharma on 21 February 2016, the average abnormal return is -4.6235%. This is possibly related to the 
advanced reaction of experimental failure. Twenty days after the announcement, the average cumulated abnormal return 
reaches -68.9988%. The average abnormal return is significantly negative at -10.90775% on the announcement day. The 
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stock price of OBI Pharma falls continuously for four days from $681 to $447.5, showing a drop of 34%. In comparison, 
another company, Medigen Biotechnology (stock ID 3176), announced a failure in blind experiment in 2014, its stock 
prices fell for 19 days continuously. The price of OBI Pharma does not fall as sharply as Medigen Biotechnology. This 
is possibly due to the positive speech by the former chair of Academia Sinica, Chi-Huey Wong, who suggests that the 
resulting data from the experiment is nice and it is an excitement from the vaccine point of view. As a result, the stock 
prices climb up slowly to the current price of $477 on 13 June 2016. 
 
 
Figure 1. AR and CAR of OBI Pharma around blind experiment failure announcement  
5.1.2 TaiMed Biologics’ Abnormal Returns 
Figure 2 shows the AR/CAR line chart of GARCH model for TaiMed Biologics. Twenty days before the announcement 
of blind experiment failure by OBI Pharma on 21 February 2016, the average abnormal return is -2.0313%. Again, it is 
possibly due to the advanced reaction of experimental failure. The average abnormal return on the announcement day is 
significantly negative at -11.2103%. On the next day, the average abnormal return rises to 3.0353%. 
Twenty days after the announcement, the average cumulated abnormal return is -58.8066%. The stock prices of TaiMed 
Biologics fall from $238 on 18 February 2016 to $183 on 23 February 2016; that is, a decrease of 23%. It is obvious 
that the price over-react to the experimental failure announcement. Not until three months later, the stock prices climb 
back to $224. 
 
Figure 2. AR and CAR of TaiMed Biologics around blind experiment failure announcement  
5.2 Unit Root Test of Sample Data 
To ensure the validity of empirical results, when testing the causality relationships, we need to ensure their cointegration 
relationship and the ranks of two variables’ time series are the same. That is, when there is I(D), a cointegration 
relationship is possible. Accordingly, the following uses ADF unit root test to examine the stationary feature of OBI 
Pharma’s price, TaiMed Biologics’ price and their price difference. The test results are shown in Table 1. 
Table 1. Unit root test of price difference between stock price of OBI Pharma and TaiMed Biologics  
Variables / Model Constant (C) Trend (T) and Constant (C) No time trend (T) and constant (C) 
A4174   -1.1158(0)   -1.9915(0) -0.4009(0) 
D(A4174)   -34.4905(0)***   -34.4775(0)*** -34.5036(0) *** 
7447 -1.1761(0) -1.6696(0)*** -0.8812(0) 
D(A7447)   -36.2009(0)***   -36.1874(0)***    -36.2046(0)*** 
A4147 -3.0050(0)** -3.7362(0)** -0.4073(0) 
D(A4147)   -34.7563(0)***   -34.7832(0)***    -34.7548(0)*** 
Note: According to Mackinnon (1991), *, **, and *** represent significance at 10%, 5% and 1% level, respectively. C, 
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T, and L are the constant, time trend and lagged period. A4174 and A7447 are the stock price of OBI Pharma and the 
price difference of OBI Pharma and TaiMed Biologics. D denotes differentiated data. 
At the original level, the variables include the stock price of OBI Pharma, price of TaiMed Biologics and their price 
differences. According to the test of lagged period with minimum SIC, most results cannot reject the null hypothesis (as 
shown in Table 1). That is, most variables are not stationary. This is probably because of the fat-tail characteristic of 
financial data and the autocorrelation in time series data. Hence, after taking the first difference, the series are stationary 
and satisfy the condition of cointegration. That is, we have obtained an I(1) stationary series which can then be 
proceeded with Granger causality test. 
5.3 Determination of Lagged Period 
First, we need to determine the lagged period of VAR model. The lagged period need be large enough to reflect its 
dynamics. However, this can reduce the degree of freedom. The most commonly used test include AIC, SC, and HQ, 
which looks for lower values. Based on the results presented in Table 2, the best lagged period is 2. 
Table 2. Lagged period test of OBI Pharma 
 Lag LogL LR FPE AIC SC HQ 
       
       0 -12372.27 NA   3626882.  20.77964  20.78817  20.78285 
1 -6807.542  11101.43  319.2458  11.44172   11.46732*  11.45136 
2 -6798.919  17.17354   316.7771*   11.43395*  11.47663   11.45003* 
3 -6797.612  2.597137  318.2133  11.43848  11.49822  11.46099 
4 -6795.345  4.500528  319.1406  11.44139  11.51820  11.47033 
       
       Note: The sample includes OBI Pharma, and the price difference of OBI Pharma and TaiMed Biologics. The sample 
period is 2015.11.23~2016.6.7. Based on the minimum AIC, this study uses two lagged periods. 
5.4 Estimation Results of VAR Model 
This section analyzes the causality relationship between OBI Pharma and the price difference between OBI Pharma and 
TaiMed Biologics based on VAR model. The results in Table 3 show that the stock price of OBI Pharma and the price 
difference lead each other by two periods. 
Table 3. Estimation results of VAR model on OBI Pharma and the price difference 
 A4174 A7447 
   
   A4174(-1)  1.206313  0.238115 
  (0.08134)  (0.06661) 
 [ 14.8306] [ 3.57468] 
A4174(-2) -0.211092 -0.226314 
  (0.08071)  (0.06609) 
 [-2.61559] [-3.42422] 
A7447(-1) -0.266174  0.682311 
  (0.09898)  (0.08106) 
 [-2.68914] [ 8.41749] 
A7447(-2)  0.269360  0.301582 
  (0.09816)  (0.08039) 
 [ 2.74402] [ 3.75156] 
C  1.489531 -1.475929 
  (2.12594)  (1.74100) 
 [ 0.70065] [-0.84775] 
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5.5 Granger Causality Test of OBI Pharma’s Price and the Price Difference 
This section analyzes Granger causality relationship between the stock price of OBI Pharma and the price difference of 
OBI Pharma and TaiMed Biologics. The results show that when lagging two periods, the two variables are Granger 
cause of each other. That is, there is a two-way relationship. In the next section, these two variables will be included in 
the program trading model to conduct back-testing and we will examine their effects on trading performance. 
Table 4. Granger causality relationship between OBI Pharma’s stock price and price difference 
Dependent variable: A4174  
        
Excluded Chi-sq df Prob. 
        
A7447  7.569756 2  0.0227 
    
    
All  7.569756 2  0.0227 
    
    
Dependent variable: A7447  
    
    
Excluded Chi-sq df Prob. 
        
A4174  13.41376 2  0.0012 
        
All  13.41376 2  0.0012 
    
5.6 Evaluation on the Inclusion of OBI Pharma’s Price and the Price Difference on Trading Performance 
In this section, we first examine Model 1 which assumes that investors have OBI Pharma’s stock market price and 
investors trade only based on RSI’s price volume diversion technical analysis. The second stage simulation is based on 
data for the period 2015.11.23~2016.2.21~2016.6.7. Based on the optimal simulated parameter from the first stage 
(2015.11.23~2015.2.21), we apply it to the second stage (2007.1.1~2016.6.7). The profit in the first stage is $161 while 
in the second stage, the profit drops to $13. The results suggest that investors cannot make profit based on past 
information and that efficient market exists (as shown in Table 5).  
Table 5. Total trading analysis of Model 1 at the first and second stage 
Unit: $ 
 Period 2015.11.23~2015.2.21~2016.6.7 
Stage First stage Second stage 
OBI Pharma Winning probability 
(Trading No. / Failing No.) 
100%(3/3) 66%(6/4) 
Net profit 161 13 
Note: First stage covers 2015.11.23~2015.2.21. Second stage covers 2015.11.23~2016.6.7. 
The results from Model 2 which includes the price difference between the two companies show that the profits of base 
company (OBI Pharma) and its corresponding company (TaiMed Biologics) significantly increase in the second stage 
(2015.11.23~2016.2.21~2016.6.7). Specifically, the profits increase from $147 to $520, showing an increase of 253%. 
Similarly, when using OBI Pharma as the base company and the corresponding company , Pharmally International 
Holding Company, the trading profits increase from $200 in the first stage to $562 in the second stage; that is, an 
increase of 181%. When OBI Pharma is paired with Grape King Bio, the trading profits increase from $215 in the first 
stage to $428 in the second stage (i.e., an increase of 99%). The pair of OBI Pharma and Chlitina shows a trading profit 
of $143 in the first stage and $173.5 in the second stage (i.e., a 21%). When OBI Pharma is paired with TTY Biopharm, 
the trading profit in the first stage is $137 and $142 in the second stage (i.e., a 3% increase). When OBI Pharma is 
paired with Ginko, the trading profit in the first stage is $129 and $487 in the second stage (i.e., a 277% increase). 
When OBI Pharma is paired with St.Shine, the trading profit in the first stage is $175 and $431 in the second stage (i.e., 
a 146% increase). The increase in trading profits differs in different pairing companies. This is likely to be due to 
different company properties in the corresponding company. 
In contrast, when the base company, OBI Pharma, is paired with ScinoPharm Taiwan, the trading profit in the first stage 
is $85, and $74 in the second stage, showing a decrease of 12%. When OBI Pharma is paired with PharmaEngine, the 
profit is $126 in the first stage and -$146 in the second stage. Therefore, including the price difference information and 
using the mean reversion characteristic, this trading strategy can lead to trading profits and the pair of OBI Pharma and 
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TaiMed Biologics gives best trading profits and highest winning probability as shown in Table 6. 
Table 6. Total trading analysis of Model 2 at the first and second stage 
Unit: $ 
Base company Corresponding company 
 
(Company property) 
Period 2015.11.23~2015.2.21~2016.6.7 
Stage 
First stage Second stage 
OBI Pharma 
(New drug) 
TaiMed Biologics  
(New drug) 
Winning probability 
(Trading No./Failing No.) 
100%(2/0) 66%(6/2) 
Net profit 147 520 
ScinoPharm Taiwan 
(Pharmaceutical 
Ingredients) 
Winning probability 
(Trading No./Failing No.) 
50%(4/2) 45%(11/6) 
Net profit 85 74 
Ginko 
(Medical equipment) 
Winning probability 
(Trading No./Failing No.) 
44%(9/5) 47%(19/10) 
Net profit 129 487 
St.Shine Optical 
(Medical equipment) 
Winning probability 
(Trading No./Failing No.) 
75%(4/1) 50%(10/5) 
Net profit 175 431 
Pharmally International 
Holding Company 
(Generics) 
Winning probability 
(Trading No./Failing No.) 
50%(4/2) 50%(10/5) 
Net profit 200 562 
Grape King Bio 
(Healthy diet) 
Winning probability 
(Trading No./Failing No.) 
71%(7/2) 52%(17/9) 
Net profit 215 428 
Chlitina   
(Aesthetic medicine) 
Winning probability 
(Trading No./Failing No.) 
50%(4/2) 21%(14/11) 
Net profit 143 173.5 
PharmaEngine 
(New drug) 
Winning probability 
(Trading No./Failing No.) 
100%(2/0) 50%(6/3) 
Net profit 126 -146 
TTY Biopharm 
(Generics) 
Winning probability 
(Trading No./Failing No.) 
80%(5/1) 33%(21/14) 
Net profit 137 142 
 
6. Conclusion  
According to Nature Biotechnology’s research report in 2014, the success of new drugs to finally being able to be sold 
in the market is only 10%. The success of cancer related medications is even lower with only 6% chance. The new drug 
of OBI Pharma has been supported by industrial, governmental and academic experts. Because of the weaknesses of 
investor behavior as pointed out by the behavioral finance theory (i.e., availability bias and representative bias), 
investors blindly believe in the support by Princo Corp.
7
 and government policy support
8
. In addition, investors are 
over-confident and have “qusi-magical thinking”. They believe that the price of OBI Pharma is likely to rise to at least a 
thousand dollar. However, in actual fact, investors are facing extreme risks.  
In recent times, the problem of information asymmetry is becoming more severe. Homo sociologicus has become a new 
thinking in current finance field. Crony capitalism becomes prevalent in emerging countries, causing an inequality in 
wealth. Therefore, this study uses two OTC market companies (OBI Pharma and TaiMed Biologics) as the case study 
companies. Using the mean reversion theory suggested by behavioral finance and program trading simulations, the 
results show that during 2015.11.23~2016.06.07, the biotechnological industry in Taiwan is not market efficient. The 
technical analysis shows that investors can make profits in the financial market using the price difference data which 
have mean reversion property. Due to the space and time limit, future research could use other bio-tech cases in Taiwan 
to conduct optimal back-testing and run the simulation. 
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Notes 
Note 1. Chi-Huey Wong and Michael Chang were classmates at MIT and the former was elected as a member of US 
National Academy of Sciences in 2006. He became the chair of NAS in 2006, and won the Wolf Prize in 2014. 
Note 2. The 2014 annual report of Cubist (which was merged by Merck & Co.) revealed that Optimer is suspected of 
violating FCPA. Interestingly, while the company was still under investigation by the US Justice Department 
and SEC, the company was able to be listed in Taiwan. (Wealth Magazine 2016/3/10, 2016/4/1, 2016/4/21 
www.wealth.com.tw; CommonWealth 2012/3/30). On 4 September 2012, the IPO price at emerging stock 
market was $45. Chi-Huey Wong did not hold any stocks. However, his daughter, Yu-Siou Wong, got 
3,000,000 shares from Ruentex Financial Group at a price of $31, lower than the IPO price of $45. 
Note 3. After retiring from the public servant, Ing-Wen Tsai served as the chairman on the board of directors of Yu 
Chang Biotech in August 2007. In May 2008, the holdings of Yu Chang Biotech were transferred to Samuel 
Yin, the chairman of Ruentex Financial Group. In April 2009, the company was renamed as TaiMed Biologics. 
In May 2016, Ing-Wen Tsai was elected as the President of Taiwan and her shareholdings are now under trust. 
Note 4. The Act allows government researchers to hold the shares of biotech and new pharmaceutical companies, and 
to be funders, directors or R&D consultants. They are not regulated by Civil Servant Work Act. The Act also 
allows these types of companies to carry IPO to obtain funds even when they have no operating income. 
Note 5. As this study focuses on the price differences between the two companies, please refer to Wealth  Magazine 
(2016/3/24, 2013/3/14,) for a discussion on their interlocking relationship in prices. 
Note 6. When the stock price reaches a new high (or low), the indicator does not. 
Note 7. Samuel Yin is ranked the 7th richest person in Taiwan and 452 in the world by Forbes 2015. 
Note 8. Biotechnological industry was the focus of government development plan. When Ing-Wen Tsai was elected as 
the Taiwan President, she and the biotechnological policy team leader, Chi-Huey Wong, visited the Nan-Kang 
Biotech Park on 24 February 2016 and President Tsai said to continue with biotechnological industry 
development. 
Note 9. According to latest stockholder report on 27 June 2016, Shih-Jen Li is no longer in the director list. Ruentex 
Financial Group holds 37.73% of shares. Michael Chang became the representative director of Ruentex 
Financial Group on the board of OBI Pharma. Fu Tai Investment became the 7
th
 largest stockholder and held 
1.66% of shares. 
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Appendix 
Appendix. Social and political ties in OBI Pharma and TaiMed Biologics 
Company            OBI Pharma 
(Breast cancer new drugs) 
TaiMed Biologics 
(AIDS new drugs) 
 
Open market IPO at $335 in the OTC market (2015.3) IPO at $115 in the OTC market (2015.11.23). 
Company name changed from Yu Chang Biotech to 
TaiMed Biologics 
Stock price range $250~$755 $146~$303 
Management team Michael Chang (Chair of the board of 
directors) 
Nien-Yuan Chang (Director and CEO, brother of 
Michael Chang) 
Main stockholder Samuel Yin (Ruentex Financial Group) holds 
33.21% of shares. 
Samuel Yin (Ruentex Financial Group) holds 16.34% 
of share. 
Development fund of Executive Yuan holds 32.24% 
of shares. 
Political ties 1. The daughter of Chi-Huey Wong holds 
3,000,000 shares (which was transferred from 
Ruentex Financial Group at $31). 
1. Ing-Wen Tsai was the chairman of Yu Chang 
Biotech, whose stockholdings was transferred to 
Ruentex Financial Group. 
 2. The fifth largest stockholder is Fu Tai 
Investment which is related to Ing-Wen Tsai’s 
family and holds 3,249,000 shares. 
 2. The chairman, Chih-Chuan Chen, is the director 
of OBI Pharma. 
 3. OBI Pharma co-operated with Academia 
Sinica and Chi-Huey Wong since 2007. In 
2014, they signed a technical skill transfer of 
carbohydrates in 2014. 
 
 4. The third largest stockholder is Shih-Jen Li9 
(of British Virgin Islands). He is a research 
managing member of Academia Sinica and is 
related to the brother of current Minister of 
Economic Affairs and sister of Michael Chang. 
 
Data source: Wealth Magazine (2016.4.21), TEJ and this study. 
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